Jazz Pharmaceuticals Reports Record $1.2B Revenue, Raises 2026 Guidance Ahead of Key Drug Launch
The Ireland-based biopharma company posted 16% year-over-year revenue growth in Q2 and increased full-year guidance as it prepares to launch zanidatamab in gastroesophageal cancer.
Strong Quarter Drives Guidance Raise
Jazz Pharmaceuticals plc reported record quarterly revenues of $1.2 billion for the second quarter of 2026, representing 16% year-over-year growth, and raised its full-year revenue guidance to $4.60-$4.75 billion (8-K filing, 2026-08-03). The Dublin-based company generated $824 million in cash from operations in the first half of 2026 and reported GAAP earnings per share of $2.78 and non-GAAP adjusted EPS of $5.71.
"Our second quarter results highlight strong execution and momentum across the business," said Renee Gala, president and chief executive officer, in the filing. The company emphasized its focus on "long-term growth as we prepare to launch Ziihera in HER2+ 1L GEA, advance the zanidatamab and Epidiolex clinical programs, and expand our pipeline."
Key Product Performance
Xywav, the company's low-sodium oxybate treatment for sleep disorders, generated net product sales of $471 million in Q2 2026, a 13% year-over-year increase (8-K filing, 2026-08-03). The product added approximately 525 net new patients during the quarter, bringing total active patients to approximately 17,125, comprised of roughly 11,275 narcolepsy patients and 5,850 idiopathic hypersomnia patients.
Epidiolex/Epidyolex, the company's cannabidiol treatment for epilepsy, posted 16% year-over-year revenue growth to $292 million in Q2 2026 (8-K filing, 2026-08-03). Jazz expanded the Epidiolex development program with clinical trials in developmental and epileptic encephalopathy, juvenile myoclonic epilepsy, and adult Lennox-Gastaut syndrome, and submitted a New Drug Application for a capsule formulation.
Zepzelca sales increased 42% year-over-year to $106 million, "driven by continued uptake of the Zepzelca and atezolizumab combination in the 1L maintenance ES-SCLC setting, partially offset by a decline in second-line use" (8-K filing, 2026-08-03). However, the company announced it will submit a labeling supplement in Q3 2026 to remove the second-line indication based on results from the LAGOON trial, though the first-line maintenance indication will remain.
Pending Launch and Pipeline Development
The FDA granted Priority Review for zanidatamab-containing combinations in first-line gastroesophageal adenocarcinoma, with a PDUFA target action date of August 25, 2026 (8-K filing, 2026-08-03). Jazz reported it is "prepared to launch Ziihera in HER2+ 1L GEA immediately following FDA approval." The drug, marketed as Ziihera (zanidatamab-hrii), generated $15 million in net product sales from its biliary tract cancer indication during Q2.
Modeyso, launched in August 2025, reported net product sales of $48 million in Q2 2026, with more than 600 patients having received the treatment through the end of the quarter (8-K filing, 2026-08-03).
Financial Position and Recent Activity
As of June 30, 2026, Jazz held $2.2 billion in cash, cash equivalents, and investments, with $4.4 billion in outstanding long-term debt and $885 million in undrawn revolving credit capacity (8-K filing, 2026-08-03). In June 2026, the company repaid $1.0 billion aggregate principal amount of 2.00% exchangeable senior notes due 2026.
MarginX data shows recent insider activity including a 6,000-share sale by director Bruce C. Cozadd and tax withholdings for executives Samantha Pearce (2,527 shares) and CEO Renee D. Gala (4,835 shares).
The company announced a preclinical research collaboration with AbCellera Biologics to develop T-cell engaging multispecific antibodies for gastrointestinal cancers and other solid tumors, with related upfront payments totaling $77 million impacting Q2 results by $0.94 per share (8-K filing, 2026-08-03).
This article was generated by MarginX from the 8-K filing on 2026-08-03. It is not investment advice.